Citeline Podcasts
Business & Economics Podcasts
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Location:
United States
Description:
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Language:
English
Episodes
Scrip's Five Must-Know Things - 5 November 2024
11/4/2024
Audio roundup of selected biopharma industry content from Scrip over the business week ended 1 November 2024. In this episode: Lilly plans DTC tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Duration:00:15:40
【3分で解説 世界のファーマ】第22回 AD治療、費用対効果に悩む英国 (Japanese-language podcast)
10/28/2024
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら 「Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No(邦訳:アルツハイマー治療薬ケサンラ承認で議論再び、薬価負担に悩む英国)」 URL: https://insights.citeline.com/pink-sheet/geography/europe/united-kingdom/deja-vu-in-england-lillys-alzheimers-drug-kisunla-gets-mhra-yes-but-nice-says-no-OX4YRPW4AFAYXAQVANZSSHURP4/ ※全文の閲覧には購読(有料)が必要です。 世界の製薬ビジネスメディアScrip(スクリップ)とは? https://www.citeline.com/ja-jp/products-services/commercialization/scrip
Duration:00:03:33
Scrip's Five Must-Know Things - 28 October 2024
10/27/2024
Audio roundup of selected biopharma industry content from Scrip over the business week ended 25 October 2024. In this episode: Merck & Co’s Modifi acquisition; scenarios for new obesity drugs; Astellas gets US approval for claudin drug Vyloy; iTeos builds TIGIT lead; and execs discuss AI in clinical trials. https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-YMAHSAK2FBBKPIPNLZGPGHWPSQ/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Duration:00:15:20
Conference Catch-Up: The Rise of Digital Therapeutics (Part 2)
10/25/2024
Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch their digital therapeutics products to market both seamlessly and with the patient in mind. That being said, we always stay up to date with the evolving landscape by attending meetings that bring together decision-makers with diverse expertise and fresh perspectives. LSX World Congress USA, which took place between September 11-12, 2024 in Boston, MA, addressed the complex investment, partnership, and innovation aspects of digital therapeutics. After attending the conference, Janelle Hart, managing editor, custom content at Citeline, sat down with principal and head of Digital Health & Access Innovation Strategy Tony Shi and consultant Eric Boyda from The Dedham Group, a Norstella company, to explore key takeaways from the meeting, what the future holds for digital therapeutics, and how Norstella and the Dedham Group are making strides in this sector to smooth the path from pipeline to patient. To listen to part 1 of this podcast, go to this link: https://soundcloud.com/citelinesounds/lsx-world-congress-usa-key-takeaways?si=6fa75aae9d7f45febcfe0bb6762a62aa&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing For more information on Norstella’s capabilities as a healthcare technology partner, visit: https://www.norstella.com/ To learn more about the Dedham Group, contact Tony or Eric at: tony.shi@norstella.com or eric.boyda@norstella.com
Duration:00:11:17
October 2024 Datamonitor Healthcare Podcast: Insights from ESMO
10/21/2024
Emma and Summer meet with oncology analysts Neha Anand, Anna Simmons, and Nkiru Ibeanu, to share insights from the European Society of Medical Oncology (ESMO) conference.
Duration:00:25:16
Scrip's Five Must-Know Things - 21 October 2024
10/20/2024
Audio roundup of selected biopharma industry content from Scrip over the business week ended 18 October 2024. In this episode: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Duration:00:15:15
Drug Fix: SubQ Drugs And Price Negotiations, GLP-1s In Court, US FDA Approach To Black Box AI
10/18/2024
Pink Sheet reporter and editors discuss an emerging pharma strategy to avoid Medicare price negotiations (:25), legal wrangling related to compounding GLP-1 drugs for obesity and diabetes (14:20), and the varying opinions of FDA officials on the acceptability of artificial intelligence models that are not fully explainable (29:08) #pharma #business More On These Topics From The Pink Sheet Keytruda, Opdivo SubQ Conversions Cloud Near-Term Medicare Negotiation Savings Forecasts: https://insights.citeline.com/pink-sheet/keytruda-opdivo-subq-conversions-cloud-near-term-medicare-negotiation-savings-forecasts-BJNQCECWVNESHGCKNPJSKVIH4I/ GLP-1s: Compounders Get Temporary Reprieve But US FDA May Be Building Stronger Case: https://insights.citeline.com/pink-sheet/legalandip/litigation/glp-1s-compounders-get-temporary-reprieve-but-us-fda-may-be-building-stronger-case-2SJVLIMS5FDERNWA7UQV3IM7JM/ US FDA Opinions Vary On AI’s Black Box Issues. Will Uncertainty Follow?: https://insights.citeline.com/pink-sheet/advanced-technologies/ai/us-fda-opinions-vary-on-ais-black-box-issues-will-uncertainty-follow-PPMN3R3FJ5BTZOXWDFHPHZVLNQ/
Duration:00:35:50
빅파마가 직면한 세포유전자 치료제 시장의 현실 (Korean-language podcast)
10/16/2024
빅파마들은 세포유전자 치료제를 출시하면서 이러한 치료의 비용과 복잡성이라는 현실적인 문제에 직면해 있습니다. 최근 개최된 메사 세포유전자 회의를 취재한 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC151041/Big-Pharma-Faces-Cell-And-Gene-Therapy-Market-Realities Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini
Duration:00:04:12
China Biopharma Podcast - 16 October 2024 (Chinese language)
10/16/2024
Dexter Yan回顾了他在国庆长假前和阿斯利康全球执行副总裁-生物制药研发负责人Sharon Barr的采访。此外,本期播客迎来了Citeline Insights团队在上海的新成员、资深记者Xu Hu。她分享了先为达生物伊诺格鲁肽的最新III期临床数据,以及中国律师对美国生物安全法案影响的分析。
Duration:00:16:25
Scrip's Five Must-Know Things - 15 October 2024
10/14/2024
Audio roundup of selected biopharma industry content from Scrip over the business week ended 11 October 2024. In this episode: making cell and gene therapies more accessible; Roche’s obesity plans; Biosecure and Indian firms; IPOs begin to recover; and Nxera looks to the future. https://scrip.citeline.com/SC151048/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Duration:00:14:37
Drug Fix: Inside Medicare Price Negotiations, New US FDA Vaccine Pathway
10/11/2024
Introduction: Pink Sheet reporter and editors discuss experts’ experience helping drug sponsors negotiate prices with CMS (:33) and the FDA’s proposal for a new pathway to update vaccines before a pandemic is declared (12:02). More On These Topics From The Pink Sheet: Perspectives From The Front Lines: Navigating The First Round Of Medicare Price Negotiation: https://pink.citeline.com/PS155353/Perspectives-From-The-Front-Lines-Navigating-The-First-Round-Of-Medicare-Price-Negotiation US FDA Proposes New ‘Inter-Pandemic’ Pathway For Updating Flu Vaccines: https://pink.citeline.com/PS155345/US-FDA-Proposes-New-Inter-Pandemic-Pathway-For-Updating-Flu-Vaccines US FDA Advisors Urge Faster Movement, mRNA Consideration, In Updating Pandemic Flu Vaccines: https://pink.citeline.com/PS155358/US-FDA-Advisors-Urge-Faster-Movement-mRNA-Consideration-In-Updating-Pandemic-Flu-Vaccines
Duration:00:24:24
Q&A Session on Psoriasis in Pediatric Patients with Dr. Valerie Welch
10/11/2024
Join us for a discussion on pediatric psoriasis and the importance of collaboration across specialties to improve treatment outcomes.
Duration:00:08:05
COPD Treatment Strategies: Q&A with Dr. Kenneth Chinsky
10/11/2024
Join us for a discussion on COPD and inhaler choice.
Duration:00:14:56
Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies
10/8/2024
Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.
Duration:00:31:59
Alpha-Synuclein Testing Comes of Age
10/4/2024
In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind Amprion, a diagnostics company, discusses the role of alpha-synuclein misfolding in neurodegenerative diseases and how early alpha-synuclein detection has the potential to mitigate the impacts of diseases ranging from Parkinson's disease to Lewy body dementia.
Duration:00:29:24
Q&A Session: PIK3CA Mutations and Breast Cancer
10/3/2024
Join us for an informative discussion about PIK3CA testing and treatment with Dr. Neil Iyengar
Duration:00:19:02
LSX World Congress USA Key Takeaways
10/2/2024
Discover the game-changing insights from the LSX World Congress USA! Join Janelle Hart, Managing Editor at Citeline, a Norstella Company, as she explores the key takeaways from the LSX World Congress USA meeting. In this episode, Janelle sits down with Tony Shi, Principal and Head of Digital Health and Access Innovation Strategy, and Eric Boyda, Consultant at The Dedham Group, to unpack the insights from this two-day event that brought together the brightest minds in biotech, medtech, and healthtech in Boston. Discover the challenges and opportunities shaping the future of healthcare technology, from groundbreaking innovations to strategic investments and transformative partnerships. Tune in now for exclusive insights and expert analysis that you won’t want to miss!
Duration:00:13:47
The Future Of Drug R&D Is Self-Driving
9/30/2024
In the latest episode of the In Vivo podcast, Alan Aspuru-Guzik, a pioneer in chemical engineering who holds many positions, talks about how he is folding in robotic automation, generative AI and quantum computing in his self-driving lab.
Duration:00:30:18
Drug Fix: Pfizer Pulls Sickle Cell Drug, ODAC Calls Back Approved Products, New AAM CEO
9/27/2024
More On These Topics From The Pink Sheet Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited: https://pink.citeline.com/PS155302/Pfizer-Withdraws-Oxbryta-But-Overall-Market-Impact-May-Be-Limited EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets: https://pink.citeline.com/PS155296/EMA-Discusses-Fatal-Events-That-Prompted-Pfizer-To-Pull-Oxbryta-From-Global-Markets New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming: https://pink.citeline.com/PS155285/New-US-FDA-Adcomm-Trend--Approved-Cancer-Meds-Get-Another-Look-When-Competitors-Coming All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer: https://pink.citeline.com/PS155300/All-Comers-No-More-US-FDA-AdComm-Supports-PDL1-Threshold-In-Esophageal-Gastric-Cancer Pazdur Calls For 'Kumbaya’ To Standardize ImmunoOncology Biomarkers: https://pink.citeline.com/PS155298/Pazdur-Calls-For-Kumbaya-To-Standardize-ImmunoOncology-Biomarkers New AAM CEO Looking To ‘Force Multiply’ For US Generics Industry: https://pink.citeline.com/PS155294/New-AAM-CEO-Looking-To-Force-Multiply-For-US-Generics-Industry
Duration:00:37:39
Challenges in the Development and Manufacturing of ADCs
9/24/2024
Executive Summary: In this podcast, Andrew Warmington, Manufacturing Editor, Citeline, joins together with industry experts, Simone Secchi, R&D Process Chemist, Olon Group, and Matthieu CULIE, Head of MAB, Pierre Fabre, to discuss the challenges in the development and manufacturing of ADCs.
Duration:00:16:24